Cencora, Inc. $COR Shares Sold by Mackenzie Financial Corp

Mackenzie Financial Corp trimmed its holdings in shares of Cencora, Inc. (NYSE:COR) by 14.7% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 149,203 shares of the company’s stock after selling 25,660 shares during the quarter. Mackenzie Financial Corp’s holdings in Cencora were worth $46,630,000 as of its most recent filing with the SEC.

Several other institutional investors have also modified their holdings of COR. Vestcor Inc boosted its holdings in Cencora by 0.5% in the third quarter. Vestcor Inc now owns 5,196 shares of the company’s stock valued at $1,624,000 after purchasing an additional 28 shares during the last quarter. Cornerstone Wealth Group LLC increased its holdings in Cencora by 1.3% during the 3rd quarter. Cornerstone Wealth Group LLC now owns 2,383 shares of the company’s stock worth $745,000 after purchasing an additional 30 shares during the last quarter. Security Financial Services INC. increased its holdings in Cencora by 2.6% during the 3rd quarter. Security Financial Services INC. now owns 1,325 shares of the company’s stock worth $414,000 after purchasing an additional 33 shares during the last quarter. Hemington Wealth Management raised its position in shares of Cencora by 12.0% in the 3rd quarter. Hemington Wealth Management now owns 327 shares of the company’s stock valued at $102,000 after purchasing an additional 35 shares in the last quarter. Finally, Quadcap Wealth Management LLC raised its position in shares of Cencora by 1.5% in the 2nd quarter. Quadcap Wealth Management LLC now owns 2,409 shares of the company’s stock valued at $722,000 after purchasing an additional 36 shares in the last quarter. Institutional investors and hedge funds own 97.52% of the company’s stock.

Insider Buying and Selling

In other Cencora news, EVP Silvana Battaglia sold 1,677 shares of Cencora stock in a transaction that occurred on Friday, December 19th. The shares were sold at an average price of $345.00, for a total transaction of $578,565.00. Following the transaction, the executive vice president directly owned 18,796 shares of the company’s stock, valued at $6,484,620. The trade was a 8.19% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Robert P. Mauch sold 5,096 shares of the stock in a transaction on Tuesday, January 20th. The stock was sold at an average price of $354.73, for a total transaction of $1,807,704.08. Following the completion of the sale, the chief executive officer directly owned 66,726 shares of the company’s stock, valued at $23,669,713.98. The trade was a 7.10% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 15,220 shares of company stock valued at $5,282,867. 0.38% of the stock is currently owned by corporate insiders.

Cencora Stock Up 0.6%

COR stock opened at $352.39 on Friday. Cencora, Inc. has a 12 month low of $252.49 and a 12 month high of $377.54. The company has a debt-to-equity ratio of 3.62, a current ratio of 0.92 and a quick ratio of 0.51. The company’s 50 day simple moving average is $355.37 and its 200-day simple moving average is $337.70. The firm has a market capitalization of $68.55 billion, a PE ratio of 42.35, a P/E/G ratio of 1.63 and a beta of 0.68.

Cencora (NYSE:COR) last announced its earnings results on Wednesday, February 4th. The company reported $4.08 EPS for the quarter, beating analysts’ consensus estimates of $4.04 by $0.04. The firm had revenue of $85.93 billion for the quarter, compared to analysts’ expectations of $86.12 billion. Cencora had a return on equity of 176.54% and a net margin of 0.50%.Cencora’s quarterly revenue was up 5.5% on a year-over-year basis. During the same quarter in the prior year, the firm earned $3.73 EPS. Equities analysts expect that Cencora, Inc. will post 15.37 earnings per share for the current fiscal year.

Cencora Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Monday, March 2nd. Stockholders of record on Friday, February 13th were issued a dividend of $0.60 per share. The ex-dividend date was Friday, February 13th. This represents a $2.40 dividend on an annualized basis and a dividend yield of 0.7%. Cencora’s payout ratio is presently 28.85%.

Analysts Set New Price Targets

A number of research firms have recently weighed in on COR. Jefferies Financial Group raised shares of Cencora from an “underperform” rating to a “buy” rating in a research report on Thursday, January 22nd. Wall Street Zen cut shares of Cencora from a “buy” rating to a “hold” rating in a report on Friday, November 28th. JPMorgan Chase & Co. increased their price objective on shares of Cencora from $417.00 to $419.00 and gave the company an “overweight” rating in a research note on Tuesday, February 10th. Barclays raised their price objective on shares of Cencora from $400.00 to $425.00 and gave the stock an “overweight” rating in a report on Friday, February 13th. Finally, Weiss Ratings raised shares of Cencora from a “hold (c+)” rating to a “buy (b)” rating in a research report on Thursday, February 5th. Eleven equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $399.00.

About Cencora

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.